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L E T T E R
Letter to the editor: “Nasal high-ﬂow versus
non-invasive ventilation in patients with chronic
hypercapnic COPD” [Letter]
This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease
J Elshof1,2
ML Duiverman1,2
1Department of Pulmonary Diseases/
Home Mechanical Ventilation, University
Medical Center Groningen, University of
Groningen, Groningen, The Netherlands;
2Groningen Research Institute for
Asthma and COPD (GRIAC), University
of Groningen, Groningen, The
Netherlands
Dear editor
We read with interest the recent article by Bräunlich et al entitled ‘Nasal high-ﬂow
versus non-invasive ventilation in patients with chronic hypercapnic COPD’
recently published in the International Journal of COPD.1 It covers an important
topic, as this is the ﬁrst study comparing non-invasive ventilation (NIV) and nasal
high ﬂow (NHF) therapy in stable hypercapnic COPD patients.
Nevertheless we would like to stress some important issues with regard to the
interpretation of the results. Firstly, we would like to address the non-inferiority
analysis of this trial. A non-inferior trial should be considered when there is a clear
advantage in any area other than effectiveness, like lower costs or fewer side
effects.2 This study shows that NHF is similarly effective in reducing PaCO2 in
stable hypercapnic patients, but the exact advantage of NHF over NIV is unex-
plained. The authors suggest that comfort may be increased by NHF since NIV is
not tolerated in some patients, however, this is not represented by the results. The
amount of drop-outs is comparable between groups, just like the assessment of the
devices and quality of life scores. Furthermore, no data is presented about the
patient’s decision on which device he or she wants to use after the study period.
Therefore, based on these results, it is unclear to us why the authors conclude that
NHF may be an alternative to NIV.
Secondly, we have reservations about the adequate application of both treat-
ments. The authors state that NIV pressure settings were adjusted to achieve
optimal tolerability and pCO2 reduction. However, compliance during NIV is
very limited with an average of 3.9±2.5 hrs/day questioning optimal tolerability,
and the effect in PaCO2 reduction is moderate. Therefore, we doubt whether NIV
was adequately administered. An exclusion criterion was prior therapy with NIV in
the last 14 days. However, no data is given about the experience with NIV at all,
which could greatly inﬂuence both compliance and drop-out rate. Also the treat-
ment of NHF was probably not optimal. The ﬂow rate was limited to 20 L/min due
to technical aspects. However, multiple studies show that the CO2 washout effect is
ﬂow-dependent where higher ﬂow leads to more CO2 washout.
3,4 The ﬂow rate of
20 L/min is likely to be inadequate for sufﬁcient CO2 reduction; although the exact
optimal ﬂow in chronic care resulting in optimal effect with good compliance is
unknown. A randomized controlled trial with adequate treatment settings and data
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with regard to optimal nHFT titration is needed to show
whether NHF is a (superior) alternative to NIV in reducing
hypercapnia and, more importantly, in achieving improve-
ment in patient-related outcomes.
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